Adverse events · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Adherence · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pain (VAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Quality of life · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Adherence · people with burn wounds likely to develop hypertrophic scarring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · newly‐diagnosed EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found